The mean of analysts' price targets for Vigil Neuroscience (VIGL) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in Vigil Neuroscience (VIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After reaching an important support level, Vigil Neuroscience, Inc. (VIGL) could be a good stock pick from a technical perspective. VIGL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
13 Mar 2025 Date | | - Cons. EPS | - EPS |
12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
12 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
13 Mar 2025 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Ivana Magovcevic-Liebisch CEO | NASDAQ (NGS) Exchange | 92673K108 Cusip |
US Country | 69 Employees | - Last Dividend | - Last Split | 7 Jan 2022 IPO Date |